Why it’s a bit surprising that the US is attending a key global flu meeting: NPR

For the previous week, about 50 flu scientists from round the world have been cramming into a convention room at a Hilton resort in Istanbul, Turkey.

Their objective is to design a flu shot that will confer the greatest safety for the subsequent flu season — beginning in the fall of 2026. Each day, they pore over reams of knowledge — about how the virus is evolving worldwide, how properly final 12 months’s shot carried out, and which strains is likely to be simpler to mass produce for a vaccine.

The assembly, convened by the World Health Organization twice a 12 months, is a important second for the WHO’s Global Influenza Surveillance and Response System.

It’s additionally “really tedious,” he says Dr. Dan Jerniganwho led the Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases from 2023 to 2025. “In order for you to make the best choice for what to put in the vaccine, you have to review a lot.”

In previous years, CDC scientists like Jernigan have performed a main function in these conferences. But after the US officially withdrew from the WHO in January, it wasn’t clear the US would take part in any WHO-led assembly. Earlier this month, the administration confirmed CDC could be sending workers regardless of the US exit from the group, albeit nearly as a substitute of in individual.

“CDC representatives will take part in the meeting to support international technical collaboration,” the Department of Health and Human Services stated in a assertion to NPR. “Their participation will solely focus on providing technical expertise, sharing surveillance data, and contributing to scientific discussions that inform vaccine strain recommendations. This participation does not change the US position on withdrawing from the WHO.”

“I think it speaks to the irreplaceable nature of these multi-country networks,” says epidemiologist Jennifer Nuzzodirector of the Pandemic Center at Brown University. The Trump administration “may bluster and say, ‘We’re not going to do this,’ but at some point, they run into reality, which is that there is no other way to protect the nation.”

Still, the US withdrawal from the WHO has challenged this global system and will in the end diminish the affect of the US in shaping the flu vaccine.

Collecting global information

At any given second, flu is spreading someplace on Earth. Each 12 months, roughly 1 billion people are contaminated. And year-round, the WHO’s surveillance system collects information from these sick sufferers in 130 nations.

Those samples are then despatched to seven bigger labs — together with the CDC in the United States. They’re known as WHO collaborating facilities, and so they attempt to make sense of all that virus information and choose strains that is likely to be appropriate for vaccines.

That global system will depend on the fixed movement of samples from many nations to these seven larger labs. WHO foots the invoice for the cargo of samples, however when its greatest funder — the US — pulled out final 12 months, the movement of influenza samples slowed down largely due to the lack of US {dollars}. Fewer samples means a dimmer view of influenza’s evolution, which may make it tougher to know which strains to place in subsequent season’s vaccine.

“There was a slight dip in the circulation of influenza vaccines around the world because of a challenge with some funding,” he stated Maria Van Kerkhoveinterim director of the division of epidemic and pandemic risk administration at WHO, at a February 11 press convention. “But we have been able to summarize the shipments around the world.”

Still, Jernigan worries about the long-term viability of the system, given WHO’s funding constraints. The current uptick “does not mean things are back to normal,” he says.

Another departure from normality is the absence of US officers actually at the convention room desk.

“You want the whole process to be very objective and quantitative, but ultimately the interaction of the different researchers is really important,” says Jernigan. CDC researchers have all the time had a lot of sway in choosing which strains to incorporate in the vaccine. But with US officers solely taking part nearly, and the US shunning worldwide collaboration extra typically, representatives from different nations could also be much less inclined to observe America’s lead.

“You want your country’s problems to be represented in what flu virus gets selected” to make sure the greatest match, says Jernigan. With the US in digital attendance solely, he says, “there’s really not an incentive for them to select the vaccine virus that represents what may be circulating in the United States.”

NPR requested the Department of Health and Human Services, which homes CDC, to deal with that concern however the company didn’t present a response.

Friday morning, WHO will announce the strains advisable by the committee for subsequent 12 months’s flu shot. Then producers begin the manufacturing course of, which takes about 9 months till the pictures are able to go.

“It’s the ultimate multilateral product of a whole global system,” says Dr. Ali Khandean of public well being at the University of Nebraska. “It’s reassuring at least that the CDC will be at these meetings,” he says, however “participating or not, we’re seeing a bleeding of influence of the US government in global health.”